By Iain Gilbert
Date: Tuesday 24 Feb 2026
(Sharecast News) - Contract development and manufacturing firm Oxford Biomedica said on Tuesday that it expects to report a strong rise in full year revenues, but signalled that underlying profitability would only be modest despite a one‑off boost from its US acquisition.
| GSK enters agreement to acquire 35Pharma | 25-Feb-2026 | 07:00 | RNS |
| Transaction in Own Shares | 25-Feb-2026 | 07:00 | RNS |
| Transaction in Own Shares | 25-Feb-2026 | 07:00 | RNS |
| Transaction in Own Shares | 25-Feb-2026 | 07:00 | RNS |
| Transaction in Own Shares | 25-Feb-2026 | 07:00 | RNS |
| Questor:Meggitt | 23-Dec-2014 | Telegraph |
| Questor :KCOM | 27-Nov-2014 | Telegraph |
| Questor :Ricardo | 31-Oct-2014 | Telegraph |
| Questor:CSR | 17-Oct-2014 | Telegraph |
| Questor:BAE Systems | 03-Sep-2014 | Telegraph |
| Price | 6,173.41 |
| Change Today | 105.15 |
| % Change | 1.73 % |
| 24-Feb-26 Close | 6,068.26 |
You are here: research